AKI, and existing clinical prevention and treatment measures such as hydration

therapy and/or administration of antioxidants N-acetylcysteine treatment and other treatments still show little effect on the prevention and treatment of CI-AKI. This study

aims to explore the effect of Danhong injection on prevention of CI-AKI.

Methods: A total of 12 867 patients, who received coronary angiography, percutaneous

coronary intervention, enhanced CT or vascular intervention in a tertiary hospital, were

enrolled for this study. Among them, 423 in the treatment group received intravenous drip

of Danhong injection, and 12 444 in the control group received routine medicine.

Propensity score matching was conducted to balance confounding factors between the 2

groups and then the prevention effect of Danhong injection on CI-AKI was compared

between them.

Results: A total of 423 pairs of patients were matched successfully. The incidence of CIAKI

in the non-Danhong control group was higher than that in the Danhong treatment

group (5.7% vs 2.4%). The difference between the 2 groups was statistically significant (P<

0.05). CI-AKI occurred maily in the Stage 1 in both the non-Danhong control group and

the Danhong treatment group. The number of patients with Stage 1 of AKI in the control

group was more than that in the treatment group, and the difference was statistically

significant (P<0.05). The incidence of AKI in Stage 2 and Stage 3 was less in both groups,

and the difference was not statistically significant (P>0.05).

Conclusion: The results of this study support the use of Danhong injection in the

prevention of the Stage 1 of CI-AKI.